Kenneth Erland Johnson - Jan 31, 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Senior Vice President, Global Development and Medical Affairs
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 03:12 PM
Previous filing
Aug 9, 2024
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +100K +58.9% $0.00 270K Jan 31, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 These shares include 1,460 shares that were purchased on June 30, 2022 and 1,700 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

Senior Vice President, Global Development and Medical Affairs